Premium
Persistent parvovirus B19 related anemia of seven years' duration in an HIV‐infected patient: Complete remission associated with highly active antiretroviral therapy
Author(s) -
Mylonakis Eleftherios,
Dickinson Brian P.,
Mileno Maria D.,
Flanigan Timothy,
Schiffman Fred J.,
Mega Anthony,
Rich Josiah D.
Publication year - 1999
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(199902)60:2<164::aid-ajh16>3.0.co;2-4
Subject(s) - medicine , parvovirus , anemia , antiretroviral therapy , pediatrics , human immunodeficiency virus (hiv) , virology , viral load , virus
A human immunodeficiency virus (HIV)‐infected individual was first diagnosed with red blood cell aplasia due to B19 parvovirus infection in late 1989. Over the subsequent seven‐year period, he received a total of 119 units of red blood cells (RBCs) and intravenous immunoglobulin every 2–3 weeks. In 1996 combination antiretroviral treatment with a protease inhibitor was initiated. He received four more units during the following two months and then required no more transfusions for the subsequent 24 months of follow‐up. His CD4 count progressively increased and DNA polymerase chain reaction for parvovirus B19 became undetectable. Aggressive antiretroviral treatment may effectively diminish transfusion requirements among HIV‐infected individuals with pure RBC aplasia resulting from parvovirus B19 infection. Am. J. Hematol. 60:164–166, 1999. © 1999 Wiley‐Liss, Inc.